Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm
Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.